Answers are grounded in this paper and cite their sources.
Platelet-rich plasma (PRP) is an alternative treatment for knee osteoarthritis (OA) patients. However, studies have shown controversial results from using this blood-derived product. This may be due to the lack of in-depth understanding of the molecular mechanisms of PRP. Immunologically, PRP normally reduces inflammation, but have been shown to increase inflammation in high doses. Therefore, in our study, we evaluated the effects of PRP on monocytes and T cells, predominant immune cells in synovial fluid of knee joints exposed to PRP. Using a direct in vitro assessment approach, we tested on various conditions of PRP usage by evaluating PRP dosage, timing of PRP exposure, immune cell subpopulation phenotype after PRP exposure and the state of immune cells prior to exposure to PRP. We show that PRP effects immune cells differently depending on the parameter evaluated. Our results demonstrate in vitro conditions that affect outcome of PRP exposure, in which knee OA patients may benefit from optimizing PRP treatment conditions as well as precautions and limitations of PRP usage.
No takes yet. Share an insight, caveat, or question.
Sengprasert et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: